Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals

Panna Vass, Balázs Démuth, Edit Hirsch, Brigitta Nagy, Sune K. Andersen, Tamás Vigh, Geert Verreck, István Csontos, Zsombor K. Nagy, G. Marosi

Research output: Review article

7 Citations (Scopus)

Abstract

In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.

Original languageEnglish
Pages (from-to)162-178
Number of pages17
JournalJournal of Controlled Release
Volume296
DOIs
Publication statusPublished - febr. 28 2019

Fingerprint

Colon
Dosage Forms
Technology
Costs and Cost Analysis
Intestinal Diseases
Patient Compliance
Inflammatory Bowel Diseases
Pharmaceutical Preparations
Biological Availability
Intestines
Oral Administration
Chronic Disease
Infection

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. / Vass, Panna; Démuth, Balázs; Hirsch, Edit; Nagy, Brigitta; Andersen, Sune K.; Vigh, Tamás; Verreck, Geert; Csontos, István; Nagy, Zsombor K.; Marosi, G.

In: Journal of Controlled Release, Vol. 296, 28.02.2019, p. 162-178.

Research output: Review article

Vass, P, Démuth, B, Hirsch, E, Nagy, B, Andersen, SK, Vigh, T, Verreck, G, Csontos, I, Nagy, ZK & Marosi, G 2019, 'Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals', Journal of Controlled Release, vol. 296, pp. 162-178. https://doi.org/10.1016/j.jconrel.2019.01.023
Vass, Panna ; Démuth, Balázs ; Hirsch, Edit ; Nagy, Brigitta ; Andersen, Sune K. ; Vigh, Tamás ; Verreck, Geert ; Csontos, István ; Nagy, Zsombor K. ; Marosi, G. / Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. In: Journal of Controlled Release. 2019 ; Vol. 296. pp. 162-178.
@article{37d6deded3ee4465a212b32e4c079430,
title = "Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals",
abstract = "In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.",
keywords = "Biopharmaceuticals, Colon targeting, Drying technology, Electrospinning, Freeze drying, Oral delivery, Spray drying, Targeted delivery",
author = "Panna Vass and Bal{\'a}zs D{\'e}muth and Edit Hirsch and Brigitta Nagy and Andersen, {Sune K.} and Tam{\'a}s Vigh and Geert Verreck and Istv{\'a}n Csontos and Nagy, {Zsombor K.} and G. Marosi",
year = "2019",
month = "2",
day = "28",
doi = "10.1016/j.jconrel.2019.01.023",
language = "English",
volume = "296",
pages = "162--178",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals

AU - Vass, Panna

AU - Démuth, Balázs

AU - Hirsch, Edit

AU - Nagy, Brigitta

AU - Andersen, Sune K.

AU - Vigh, Tamás

AU - Verreck, Geert

AU - Csontos, István

AU - Nagy, Zsombor K.

AU - Marosi, G.

PY - 2019/2/28

Y1 - 2019/2/28

N2 - In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.

AB - In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.

KW - Biopharmaceuticals

KW - Colon targeting

KW - Drying technology

KW - Electrospinning

KW - Freeze drying

KW - Oral delivery

KW - Spray drying

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=85060334841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060334841&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.01.023

DO - 10.1016/j.jconrel.2019.01.023

M3 - Review article

AN - SCOPUS:85060334841

VL - 296

SP - 162

EP - 178

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -